Study of a new drug combination for metastatic colorectal cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug (HRS-2189) combined with two other medications (Adebrelimab and BP102) for people whose colorectal cancer has spread. It aims to see if this combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with colorectal cancer that has spread to other parts of your body (metastatic).
- You are in generally good health, able to do most daily activities (ECOG score 0 or 1).
- You have at least one tumor that can be measured on a scan.
- You have not had another cancer in the last 5 years, except for certain cured skin cancers or early cervical cancer.
- You do not have active brain or spinal cord tumors that cause symptoms.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the immunotherapy drug adebrelimab to standard chemotherapy plus bevacizumab can help people with a specific type of metastatic colorectal cancer that cannot be removed by surgery. It is for patients whose tumors are microsatellite stable (MSS) or have normal mismatch repair (pMMR).
This trial tests a combination of three drugs (SHR-1701, SHR2554, and BP102) to see if they work better together for people with metastatic colorectal cancer. It is for those who have not been treated with similar immune checkpoint drugs before.
This trial tests a mix of three drugs (sintilimab, bevacizumab, and decitabine) for people with advanced colorectal cancer that has a stable or low amount of genetic change. It’s for those whose cancer has grown after at least two prior treatments, and who have not had immunotherapy before.
This trial tests a new combination of three drugs for people with advanced colorectal cancer that has not responded to previous treatments. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests whether combining two drugs—bevacizumab and adebrelimab—can help people with a specific type of colorectal cancer that has spread and is MSS-type. It's for patients who have already had standard chemotherapy and have tumors that show certain genetic features.
This trial tests a new drug combination (SR-8541A, botensilimab, and balstilimab) for people with a specific type of metastatic colorectal cancer that is not MSI-high. It aims to see if this combination can help when other treatments have stopped working.
Hear when a new Colorectal Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.